| Code | CSB-RA001950MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to MEDI-1814, designed to target amyloid precursor protein (APP), a type I transmembrane protein that plays a central role in neuronal development and synaptic plasticity. APP undergoes sequential proteolytic processing through amyloidogenic and non-amyloidogenic pathways, with aberrant cleavage leading to the generation of amyloid-beta (Aβ) peptides that accumulate as senile plaques in the brain. Dysregulation of APP processing is fundamentally implicated in the pathogenesis of Alzheimer's disease and related neurodegenerative disorders, making it a critical therapeutic target for understanding disease mechanisms.
MEDI-1814 is a clinical-stage therapeutic antibody developed to selectively modulate APP processing and reduce pathogenic Aβ production. This biosimilar provides researchers with a valuable tool for investigating APP biology, studying amyloidogenic pathways, and exploring potential therapeutic interventions in Alzheimer's disease models. It supports a range of in vitro and in vivo research applications focused on neurodegeneration, protein processing mechanisms, and antibody-based therapeutic strategies.
There are currently no reviews for this product.